| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.52▲ | 0.52▲ | 0.51▲ | 0.52▲ | 0.50▲ |
| MA10 | 0.51▲ | 0.50▲ | 0.49▲ | 0.49▲ | 0.51▲ |
| MA20 | 0.49▲ | 0.47▲ | 0.46▲ | 0.49▲ | 0.55▼ |
| MA50 | 0.45▲ | 0.47▲ | 0.48▲ | 0.51▲ | N/A |
| MA100 | 0.47▲ | 0.49▲ | 0.51▲ | 0.58▼ | N/A |
| MA200 | 0.54▼ | 0.65▼ | 0.73▼ | 0.76▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.009▲ | 0.011▲ | 0.007▲ | 0.019▲ |
| RSI | 62.170▲ | 61.603▲ | 60.693▲ | 53.435▲ | 43.764▼ |
| STOCH | 85.758▲ | 91.605▲ | 87.226▲ | 85.930▲ | 43.711 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -10.854▲ | -42.441 |
| CCI | 128.515▲ | 122.643▲ | 145.835▲ | 112.114▲ | 11.551 |
|
Thursday, September 19, 2024 12:03 PM
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation.
|
|
Thursday, September 19, 2024 11:44 AM
Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. Analyst Price Forecast Suggests 10.13% Upside As of ...
|
|
Thursday, September 19, 2024 09:59 AM
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/09/24 | 0.529 | 0.54 | 0.515 | 0.5222 | 6,248 |
| 18/09/24 | 0.4934 | 0.535 | 0.48 | 0.535 | 1,903 |
| 17/09/24 | 0.504 | 0.538 | 0.48 | 0.5201 | 6,847 |
| 16/09/24 | 0.4929 | 0.5386 | 0.4929 | 0.512 | 15,371 |
| 13/09/24 | 0.49 | 0.5386 | 0.4695 | 0.499 | 968 |
| 12/09/24 | 0.4051 | 0.52 | 0.4051 | 0.4963 | 250,900 |
| 11/09/24 | 0.4088 | 0.47 | 0.3813 | 0.46 | 55,356 |
| 10/09/24 | 0.46 | 0.4764 | 0.376 | 0.4021 | 215,671 |
| 09/09/24 | 0.5249 | 0.525 | 0.45 | 0.4581 | 49,721 |
| 06/09/24 | 0.475 | 0.52 | 0.47 | 0.52 | 2,961 |
|
|
||||
|
|
||||
|
|